SCHEMBL26102213

SCHEMBL26102213

COc1cc2c(-c3ccc(NC(=O)Cn4cc(C(C)C)nn4)cc3)ncnc2cc1OCCCN1CCN(C)CC1

nearest known ligand 0.54

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ EGFR P00533 19/20 0.54
▸ KDR P35968 19/20 0.54
▸ PDGFRB P09619 3/20 0.47
▸ FLT4 P35916 3/20 0.47
▸ AURKB Q96GD4 3/20 0.47
▸ AURKA O14965 2/20 0.47
▸ ERBB2 P04626 2/20 0.47
▸ TEK Q02763 2/20 0.47
▸ PLK4 O00444 1/20 0.47
▸ GAK O14976 1/20 0.47
▸ EPHB6 O15197 1/20 0.47
▸ STK10 O94804 1/20 0.47
▸ NTRK1 P04629 1/20 0.47
▸ LCK P06239 1/20 0.47
▸ CSF1R P07333 1/20 0.47
▸ KIT P10721 1/20 0.47
▸ FGFR1 P11362 1/20 0.47
▸ SRC P12931 1/20 0.47
▸ PDGFRA P16234 1/20 0.47
▸ FLT1 P17948 1/20 0.47

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL31137774 0.89 EGFR (0.54) EGFRKDR
SCHEMBL26101800 0.87 EGFR (0.52) EGFRKDRKITSRCPDGFRA
SCHEMBL29238258 0.86 KIT (0.47) EGFRKDRPDGFRBFLT4AURKA
SCHEMBL26101516 0.85 KDR (0.63) EGFRKDRPDGFRBFLT4AURKB
SCHEMBL26101448 0.83 KIT (0.44) EGFRKDRPDGFRBFLT4AURKA
SCHEMBL26101259 0.82 EGFR (0.44) EGFRKDRPDGFRBFLT4CSF1R
SCHEMBL30394220 0.82 EGFR (0.60) EGFRKDRPDGFRBFLT4AURKB
SCHEMBL26101658 0.82 EGFR (0.60) EGFRKDRPDGFRBFLT4AURKB
SCHEMBL26101324 0.82 EGFR (0.44) EGFRKDRPDGFRBFLT4CSF1R
SCHEMBL29238608 0.82 KIT (0.45) EGFRKDRPDGFRBFLT4ERBB2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20260138959-A1 QUINAZOLINE DERIVATIVE COMPOUND AND USE THEREOF VORONOI INC (KR) 2026-05-21 — — US claimed
EP-4424675-A1 QUINAZOLINE DERIVATIVE COMPOUND AND USE THEREOF Voronoi Inc. (KR) 2024-09-04 — — EP claimed
US-20260138959-A1 QUINAZOLINE DERIVATIVE COMPOUND AND USE THEREOF VORONOI INC (KR) 2026-05-21 — — US disclosed
EP-4424675-A1 QUINAZOLINE DERIVATIVE COMPOUND AND USE THEREOF Voronoi Inc. (KR) 2024-09-04 — — EP disclosed
WO-2023075529-A1 QUINAZOLINE DERIVATIVE COMPOUND AND USE THEREOF 보로노이바이오 주식회사 2023-05-04 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20260138959-A1 QUINAZOLINE DERIVATIVE COMPOUND AND USE THEREOF PDGFRA, KIT, PDGFRB EGFR 79/4885KDR 5/4885PDGFRB 3/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback